BUSPIRONE HYDROCHLORIDE

Post-LOE

buspirone hydrochloride

Oxford Drug Design
ANDAORALTABLET
Approved
May 2002
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
2

Mechanism of Action

CLINICAL PHARMACOLOGY The mechanism of action of buspirone is unknown. Buspirone differs from typical benzodiazepine anxiolytics in that it does not exert anticonvulsant or muscle relaxant effects. It also lacks the prominent sedative effect that is associated with more typical anxiolytics. In…

Indications (5)

anxiety disordersthe short-term relief of the symptoms of anxietyanxietyschizophreniainsomnia

Clinical Trials (2)

NCT00840398Phase 1Completed

Buspirone Hydrochloride 30mg Tablets, Non-Fasting

Started Dec 2001
24 enrolled
Healthy
NCT00840606Phase 1Completed

Buspirone Hydrochloride 30mg Tablets, Fasting

Started Dec 2001
70 enrolled
Healthy
Company
Oxford Drug Design
Oxford Drug Design
UK - Oxford
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers